ImmunoGen breast cancer drug successfully meets midstage goals
Apr 14, 2011
Drug-maker ImmunoGen Inc. is developing T-DM1 with biotechnology firm, Roche, and the drug has successfully met midstage goals, according to Business Week.
The drug uses Herceptin, which is produced by Roche's Genentech and is made up of the drug known as trastuzumab. Hercepting injection is used to combat breast cancer metastasis and prevent cancer recurrence, according to the NIH.
The study found that women who used T-DM1 were less likely to experience a return of breast cancer compared to patients using solely Herceptin and chemotherapy.
"This top-line information about T-DM1's performance in the first-line setting is very encouraging and adds to the favorable efficacy and safety data reported across a number of T-DM1 studies," said Daniel Junius, ImmunoGen President and CEO.
The study looked at 137 patients and used T-DM1 as an initial treatment for breast cancer. The drug could potentially be used as a secondary treatment as well.
Shares of ImmunoGen climbed upon the news of the study results.